GSK-3 抑制剂：一类用于治疗阿尔茨海默病的新型药物

Title:GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment

Volume: 22 Issue: 15

关键词: 阿尔茨海默病、GSK-3、GSK-3 抑制剂、Tau、β-淀粉样蛋白、神经退行性疾病、蛋白激酶。

摘要: Alzheimer’s disease (AD), a chronic neurodegenerative disease, is the most common form of dementia that causes cognitive function impairment, including memory, thinking, and behavioral changes that ultimately lead to death. The overactivation of GSK-3, an enzyme from the proline/serine K_i ^{NS family, has been associated with hyper-phosphorylation of tau proteins. The self- -assembly of hyper-phosphorylated tau proteins to form tangles of straight and helical filaments is known to be involved in AD. Therefore, GSK-3 has been considered a potential target of novel drug discovery for AD treatment. Research on the development of GSK-3 inhibitors has received enormous attention from the vast scientific community because they are targeted for AD and other diseases, including type 2 diabetes, cancers, stroke, Parkinson’s disease and bipolar disorder. Various drugs of both synthetic and natural origins have been designed to inhibit GSK-3 activity. However, there is a need to develop novel drug candidates that can selectively inhibit GSK-3. Hence, this review summarizes the potential of GSK-3 inhibitors for AD therapy and discusses the structure- activity relationship of current drug molecules and the potential problems associated with them.}

Cite this article as:

GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment, Current Drug Targets 2021; 22 (15) . https://dx.doi.org/10.2174/1389450122666210114095307